Inflammatory markers and cognitive performance in patients with schizophrenia treated with lurasidone

Journal article

Peer reviewed

B.J Miller, A Pikalov, C Siu, M Tocco, J Tsai, P.D Harvey and A Loebel

European neuropsychopharmacology, Vol.29, pp.S416-S417

2019

Metrics

12 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.21 Psychiatry; 1.21.24 Schizophrenia
Web Of Science research areas: Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
ESI research areas: Neuroscience & Behavior

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Inflammatory markers and cognitive performance in patients with schizophrenia treated with lurasidone
Creators: B.J Miller - Medical College of Georgia- Augusta University, Psychiatry, Augusta, USA
A Pikalov - Sunovion Pharmaceuticals Inc., Global Medical Affairs- Psychiatry, Fort Lee, USA
C Siu - COS and Associates Ltd., Data Science, Hong Kong, Hong Kong
M Tocco - Sunovion Pharmaceuticals Inc., Global Medical Affairs, Marlborough, USA
J Tsai - Sunovion Pharmaceuticals Inc., Clinical Development, Fort Lee, USA
P.D Harvey - University of Miami Miller School of Medicine, Psychiatry and Behavioral Sciences, Miami, USA
A Loebel - Sunovion Pharmaceuticals Inc., Global Clinical Development, Fort Lee, USA
Publication Details: European neuropsychopharmacology, Vol.29, pp.S416-S417
Publisher: Elsevier B.V
Academic Unit: Miller School of Medicine; UMMG Dept of Psychiatry & Behavioral Sciences
Language: English
Resource Type: Journal article
Record Identifier: 991031600593702976